NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice

Overview of attention for article published in Frontiers in Nutrition, July 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter: 4 X users

patent: 1 patent

Citations

dimensions_citation: 19 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 12,738 followers.

NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice https://t.co/CkZV73pvct

31 Jul 2021

Reply Repost Favourite

31 Jul 2021

Reply Repost Favourite

30 Jul 2021

Reply Repost Favourite

New Research: NU9056, a KAT 5 Inhibitor, Treatment Alleviates Brain Dysfunction by Inhibiting NLRP3 Inflammasome Activation, Affecting Gut Microbiota, and Derived Metabolites in LPS-Treated Mice: Background: The pathogenesis of… https://t.co/f1ycKnT0hy #Nu

14 Jul 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.